RGS9-2: probing an intracellular modulator of behavior as a drug target.

Abstract

Regulators of G-protein signaling (RGS proteins) comprise a large family of signal transduction molecules that modulate G-protein-coupled-receptor (GPCR) function. Among the RGS proteins expressed in the brain, RGS9-2 is very abundant in the striatum, a brain region involved in movement, motivation, mood and addiction. This protein negatively modulates signal transduction thus playing a key part in striatal function and resultant behavioral responses. In particular, there is evidence of important interactions with mu-opioid- and dopamine D(2)-receptor signaling pathways. Several studies indicate that manipulations of RGS9-2 levels in the striatum might greatly affect pharmacological responses. These findings indicate that treatment strategies targeting RGS9-2 levels or activity might be used to enhance responses to drugs acting at GPCRs and/or prevent undesired drug actions.

DOI: 10.1016/j.tips.2008.11.006

Cite this paper

@article{Traynor2009RGS92PA, title={RGS9-2: probing an intracellular modulator of behavior as a drug target.}, author={John R. Traynor and Dimitra Terzi and Barbara J. Caldarone and Venetia Zachariou}, journal={Trends in pharmacological sciences}, year={2009}, volume={30 3}, pages={105-11} }